biotx.ai
Unlocking the full therapeutic potential of the human genome through algorithms
Unlocking the full therapeutic potential of the human genome through algorithms
HELLSICHT is a Germany-based biotechnology startup aspiring to unlock the full therapeutic potential of the human genome through algorithms. Their slogan "Unlocking the full therapeutic potential of the human genome through algorithms" reflects their core mission. Since its establishment in 2017, the company has been dedicated to delivering predictive biomarkers as a basis for decision support in precision medicine. Leveraging novel, state-of-the-art machine learning approaches tailored for complex pattern identification in biomedical data, HELLSICHT aims to revolutionize the field of biotechnology and pharmaceuticals. Their recent Convertible Note investment in 05 April 2023 from the Oxford Angel Fund demonstrates their appeal to notable investors. This signifies a great potential and confidence in the company’s vision and business model.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | Unknown | 1 | Oxonian Ventures | 05 Apr 2023 |
| Seed Round | Unknown | 1 |
|
08 Nov 2021 |
| Non Equity Assistance | Unknown | 1 |
|
17 Jun 2019 |
| Seed Round | Unknown | 1 |
|
02 Dec 2017 |
No recent news or press coverage available for biotx.ai.
We care about your data, and we'd love to use cookies make your experience better.
